Role of Microglia and Astrocytes in Spinal Cord Injury Induced Neuropathic Pain

Gurwattan S. Miranpuri1, Parul Bali2, Justyn Nguyen1, Jason J. Kim1, Shweta Modgil3, Priya Mehr4,5, Seah Buttar1, Greta Brown1, Noemi Yutuc1, Harpreet Singh1, Aleksandar Wood1, Jagtar Singh4, and Akshay Anand3,5,6

Abstract

Background: Spinal cord injuries incite varying degrees of symptoms in patients, ranging from weakness and incoordination to paralysis. Common amongst spinal cord injury (SCI) patients, neuropathic pain (NP) is a debilitating medical condition. Unfortunately, there remain many clinical impediments in treating NP because there is a lack of understanding regarding the mechanisms behind SCI-induced NP (SCINP). Given that more than 450,000 people in the United States alone suffer from SCI, it is unsatisfactory that current treatments yield poor results in alleviating and treating NP.

Summary: In this review, we briefly discussed the models of SCINP along with the mechanisms of NP progression. Further, current treatment modalities are herein explored for SCINP involving pharmacological interventions targeting glia cells and astrocytes.

Key message: The studies presented in this review provide insight for new directions regarding SCINP alleviation. Given the severity and incapacitating effects of SCINP, it is imperative to study the pathways involved and find new therapeutic targets in coordination with stem cell research, and to develop a new gold-standard in SCINP treatment.

Keywords
Spinal cord injury, Neuropathic pain, Microglia, Astrocytes, Matrix metalloproteinases, JNK, P2 receptors

Received 13 April 2021; accepted 3 August 2021

Introduction

The nature and extent of a spinal cord injury (SCI) is diverse and complicated. There are many symptoms, including, but not limited to, paralysis, myelopathy, and damage to white matter and grey matter. The complexity of injury is increased manifold as nerve fiber damage compromises sensation and motor signal transmittance to and from the brain, while grey matter damage results in segmental losses of interneurons. The utilization of corticosteroid (methylprednisolone sodium succinate), surgical interventions, and physiotherapy are the only methods for treatment in current health care, and these methods display limited success.1 Yet, recent advances in the fields of stem cell biology have revolutionized neuroprotective and regenerative interventions.

Neuropathic pain (NP), because of its relatively unexplored molecular mechanism and widespread clinical morbidity, is extremely debilitating for SCI patients. In addition, NP is extremely resistant to treatment with current analgesic drugs, solidifying the necessity to find efficacious treatment options. Acknowledged in the current research are the emerging role of WNK1; cation-dependent chloride transporters (NKCC1) activation and inhibition by bumetanide2,3; cannabinoid receptor (CB2) and anti-hyperalgesia effect of WIN...
Role of Glial Cells in Neuropathic Pain

Earlier pain induced after SCI was thought to be a result of anatomical, neurochemical, and excitotoxic alterations with changes in ion channels. However, the current treatment modalities targeting neuronal activity by modifying the ion channels proved to be inadequate. The focus was then shifted to neuron dysfunction, which until recently was thought to arise from neuroimmune modulation. Recent studies have made it evident that NP development involves complex mechanisms involving not only neuronal cells but also glial cells. These modulations are mainly contributed by the resident glial cells of the spinal cord. Astroglia and microglia are main cells attributing to inflammatory response and have been implicated in pain induction after injury. SCI is followed by extensive neuroinflammation because of activation of these glial cells releasing chemokines and cytokines. Thus, targeting neuroinflammation may open new treatment avenues for management of NP.

Implication of Microglia in Spinal Cord Injury-Induced Neuropathic Pain

Microglia play an important role in the maintenance and health of the CNS and are known to aid in neuronal differentiation and in the production of synaptic bonds. Microglia develop early in the embryonic yolk sac, contribute to brain development, and continue their work much into adulthood. The role of microglia in peripheral pain is well studied, and activation of these cells after partial sciatic nerve ligation, spinal nerve ligation, and sciatic nerve inflammation have been found. Fractalkine, a microglial activator, induces allodynia and hyperalgesia shown by behavioral parameters. Like peripheral injury, microglial activation has been reported in SCI and showed that the microglia shift from resting to an activated state in rats undergone T9 spinal cord contusion injury. These activated microglia contribute to chronic pain induction and maintenance after SCI. Microglial response at different timepoints determined that activation plateaued between two and four weeks after injury. In spinal nerve injury models, hyperactive microglia were found to increase the levels of P2X4 receptors. The expression was specific to microglia cells, while neuron and astrocytes remained unaffected. P2X4 are purinergic receptors, and ATP is a known mediator of NP; therefore, it was suggested that upregulation of these receptors is linked to NP induction. However, the mechanism was not fully understood. Later, it was demonstrated that these receptors on stimulation lead to Brain-derived Neurotropic Factor (BDNF) secretion from activated microglia. It was further found to affect NMDA receptors’ NR1 subunit in spinal cord dorsal horn neurons, which results in pain. This was supported by the studies in P2X4-deficient mice that, after peripheral nerve injury induction, display impaired BDNF signaling and lack hyperalgesia. Another molecule, CCL21, was shown to rapidly express in injured sensory neurons. Further investigations in CCL21-deficit mice established the link between CCL21 and microglial P2X4. It was found that these deficit mice lack allodynia and reported with lower P2X4 expression. Later it was...
demonstrated that a wide range of purinergic receptors were activated by ATP in response to nerve injury that led to microglial activation and subsequently NP (Multiple PY2). Molecular mechanism, such as those involving MAPK, ERK, and p38, have been implicated in signal transduction from microglial activation. For example, ROCK activation in spinal microglia has been shown with p38 MAPK activation and induction of NP. Thus, it can be suggested that spinal microglia play a role in NP induction and may be explored for their use as potential targets for chronic pain treatment.

Long-term pain sensation is maintained by neuronal-glial interactions. Early phase and chronic phase are separately maintained by different mechanisms. Mice with nerve injury had persistent microglia activation for more than three months in the spinal cord. It was seen that microglia involvement is far beyond the cytokine and chemokine signaling that last for a limited period. Chronic inflammation by microglia, when targeted with immunotoxin Mac1-saporin, helps in pain reversal. Evidently, microglia are strongly tied to inducing NP through MMP-9 activation in the spinal cord. The activation and deactivation of microglia through MMP-9 injection and inhibition has been demonstrated. As an example, NAC attenuated remifentanil-induced postoperative hyperalgesia via inhibiting the cleavage of IL-1β, a substrate of MMP-9 in DRG, significantly inhibiting glial activation and neuron excitability in the spinal dorsal horn.

**Implication of Astrocytes in Spinal Cord Injury-Induced Neuropathic Pain**

Astrocytes are cells lining the neurons and are involved in neuroinflammation by activating astrogliosis. Like microglia, long-lasting changes in astrocytes have been observed in in-vivo models of SCI. Astrogliosis is associated with development and NP persistence. Various mechanisms have been proposed through which astrogliosis contribute in NP. Astrocyte-related markers such as glial fibrillary acidic protein (GFAP) and aquaporin 4 are elevated in SCI rats. Upregulated levels of GFAP and p38 MAPK were also reported below and at level of injury, further supporting astrogliosis role in pain (Carlton et al. 2009).

Elevation of Connexin-43 (CX-43), a gap junction protein, points toward increased connectivity between adjacent astrocytes. Wang and Xu discussed the role and association of Cx-43 and pannexin channels in SCINP, and they concluded that CX-43 is an emerging therapeutic target for NP. Studies have also shown that these effects are a result of upregulation of Tropomyosin-related kinase B.T1 (TrkB.T1)-driven astrocytes (Figure 1). TrkB.T1 is an isoform of TrkB receptors that are expressed on astrocytes and an increased number of TrkB.T1+ cells after injury were reported that sustained through eight weeks. In concordance with this, TrkB.T1 deletion in astrocytes led to reduced astrocyte proliferation in thoracic contusion SCI and improved hind limb withdrawal threshold. Role of chemokines in activation of astrocytes has also been implicated in establishment of NP. Animals with spinal nerve ligation (SNL) have elevated levels of chemokines. CXCL13 has been shown to activate spinal astrocyte via another chemokine CXCR5. CXCR5−/− mice demonstrated lack of NP following SNL as CXCR5 was essential for activation of glial cells. Thus, neuron-astrocyte interaction lead to CXCL13 production by neuron cells that further activates astrocytes through CXCR5, inducing NP. c-Jun N-terminal kinase (JNK)/monocyte chemoattractant protein-1 (MCP-1) pathway in astrocytes is also found to be involved in NP development. A separate study bridges the role of both JNK1/2 and MMPs in NP where inhibition of astrocyte activation in the spinal cord by tetramethylpyrazine (TMP) prevented CCI-induced neuroinflammation. These findings demonstrate implication of JNK-MMP-2/9 in attenuating NP. In a mouse CPIP model, phosphorylated c-jun N-terminal kinase 1/2 (pJNK1/2) is downstream of spinal MMP-2. The MMP-2 inhibitor reversed the increase of glial fibrillary acidic protein (GFAP), the astrocyte biomarker, and pJNK1/2 on day three post injury. The findings in this study include (a) increase in GFAP, but no significant effect on ionized calcium binding adaptor molecule 1, IBA1, a reactive microglial biomarker; (b) inhibition of astrocytes with fluorocitrate, but no inhibition of microglia with minocycline results in attenuation of alldynia in injured mice correlated with enhanced spinal levels pJNK1/2; (c) pJNK1/2 inhibitor, SP600125, showed decline in allodynia in injured mice; and (d) increased expression levels of spinal MMP2, mainly NeuN a neuron biomarker; and (e) intrathecal administration of MMP-2 inhibitor, APR 100, resulting in delayed alldynia and decreased spinal levels of GFAP and pJNK1/2. Recent studies have also indicated that neuroinflammation plays a vital role in the occurrence and promotion of NP and that anti-inflammatory therapy has the potential to relieve the pain. Thus, both microglia and astrocytes are linked to NP induction. In the next section, we will review studies that targeted these cells to ameliorate NP.

**Glial Cells as Therapeutic Targets**

**Microglial Targets for Alleviating NP**

Regulating microglia activity is thought to be a possible approach in impeding chronic pain progression. As discussed, activated microglia through production of various immunoinflammatory molecules contributes to a state of chronic pain. These molecules lead to the activation of intracellular cascades in microglia cells generating and sustaining chronic pain. Earlier studies with the goal of managing pain have explored the neuropathic roles of microglia and pharmacological interventions targeting activation of these cells.

**Inhibiting p38 MAPK**

Decades earlier, the glia cell-modifying functions of drugs like fluorocitrate and propentofylline had been shown to...
reduce pain sensitivity. The drugs however did not distinguish glial cell types and which cells are responsible for pain sensitivity. Mounting evidence demonstrates the activation of microglia cells as exhibited by elevated levels of markers such as CD 11b and Iba 1. Phosphorylated p38 MAPK kinase expression was also another characteristic feature of SCI and is believed to be another key regulator of NP. It was reported that p38MAPK was activated only in microglia after SCI. With the activation of p38, microglia produce proNGF via the p38MAPK-mediated pathway. When Minocycline was administered, it showed significant reduction in proNGF secretion. P2X7 receptor effects are mediated through the convergence to p38 MAPK signaling. However, while in P2X4 receptor-signaling, BDNF is a key molecule, P2X7 receptor signaling is regulated by the release of interleukin-1β and cathepsin S from microglia. Apart from P2X receptors, microglia are known to have a wide range of P2Y receptors such as P2Y1, P2Y2, P2Y4, P2Y6, and P2Y12. P2Y12 receptor is involved in eliciting pain sensitization. Administration of 2Me-SADP, P2Y12 receptor agonist, mimics similar pain behavior in rats as nerve-injured animals. Moreover, genetic manipulation of P2ry12 gene or suppression of expression through antisense oligonucleotides prevents mechanical allodynia. Thus, it can be implicated that purinergic receptor mediated pain induction is an upstream process that converges to p38 MAPK signaling cascade.

Inhibition of Expression of Matrix Metalloproteinase/Induction of TIMPs Through Microglia

In peripheral nerve injury, Chattopadhyay reported a dramatic increase of MMP-9. It was found that this upregulation of MMP-9 was linked with proinflammatory cytokines: TNF-α and IL-1β. Deletion of MMP-9 gene leads to significant reduction in NP, which further suggests the role of MMP in pain induction. This opens a new avenue for NP management by MMP targeting. Mice with chronic constrictive injury (CCI)-induced NP, when treated with N-acetyl-cysteine (NAC), showed reduction in NP via a mechanism of MMP inhibition. Both in vitro and in vivo experiments showed suppression of the activity of MMP9 and MMP2. NAC blocked the maturation of interleukin-1β, a substrate of MMPs, inhibiting the phosphorylation of protein kinase Cγ, NMDAR1, and mitogen-activated protein kinases. In this mechanism, NAC inhibited microglia activation but with no effect on astrocytes, thus demonstrating a safe and effective approach via strong inhibition of MMPs. TIMPs are endogenous inhibitors of MMPs comprising of four inhibitors: TIMP1, TIMP2, TIMP3, and TIMP4. Of these, TIMP1 and TIMP2 have specifically reported to alleviate the pain behavior by inhibiting MMP 2 and MMP 9. Evidence of other small molecule inhibitors of MMPs that are employed to reduce the NP are reviewed.

Other Microglial Targets in Alleviation of NP

Although proliferation of microglia is correlated with NP, candidate molecules for this activation of spinal microglia remain elusive. A recent study reported that peripheral nerve injury induces microglial proliferation and pain through de novo expression of colony-stimulating factor 1 (CSF1) sensory neurons. It was discovered that CSF1 binds to CSF1R...
receptors in microglia, which then activates and increases proliferation of microglia. Furthermore, they found that microglial membrane adapter protein, DAP12, is downstream of CSF1, which induces pain. Likewise, recombinant Macrophage-CSF injection in rats induced microglial proliferation and development of mechanical allodynia, suggesting the role of M-CSF as a candidate molecule for induction of microglia proliferation. Furthermore, Platelet-activating factor (PAF)/PAF receptor signaling has been implicated in peripheral nerve injury in spinal cord signaling. Autocrine or paracrine effects of PAF among the activated microglia and neurons have been shown in NP induction. A recent study demonstrated that partial sciatic nerve ligation-induced pain can be attenuated by deficiency of lysophosphatidyl choline acyl transferase 2 (LPCAT2), a PAF biosynthetic enzyme. Explored mechanisms exhibited LPCAT2 in wild-type spinal cord microglia, with no expression of LPCAT2 in LPCAT2-KO mice reduced spinal PAF expression. Also, pretreatment with PAF receptor antagonist ABT-491 showed a decline in ATP-stimulated PAF biosynthesis in macrophages designated as PAF–pain loop, thus demonstrating a novel therapeutic target that may lead to alleviation of NP.

Astrocytes Targets for Alleviating NP

Microglia have long been implicated in NP, unlike astrocyte involvement, which is still a new concept. Astrocyte activation is dependent on interaction between these cells and neurons, as well as release of factors from both cell types. In CPIP animal model, fluorocitrate inhibited activation of astrocyte in mice and attenuated the development of allodynia in them, while minocycline (microglia inhibitor) could not show the same effects. Thus, drugs targeting astrocytes are being explored for NP regulation rather than microglial pathway.

Astrocytic Glutamine-Signaling

Glutamate transporters are involved in pathological pain induction, and spinal astrocyte glutamate transporters are downregulated in pain. This aspect is also explored for possible therapy in chronic pain. In vivo imaging in rodent models has reported the role of metabotropic glutamate receptor five (mGlur5) signaling in S1 astroglia (Figure 1). Activation of this pathway induces alldynia, which is reversed by blocking the signaling. Adenoviral infusion of GLT1 gene results in overexpression in astrocytes. Spinal GLT-1 gene transfer prevented the induction of partial sciatic nerve ligation-induced allodynia. Consistent with these findings,riluzole inhibited NP by reducing extracellular glutamate by EAATs. Moreover, ceftriaxone also prevented allodynia by selectively upregulating GLT-1 expression. Taken together, it can be implicated that decreased astrocytic excitatory amino acid transporter in the spinal cord led to activation of glutamatergic synaptic pathway related to pathological pain. Propentofylline increases GLT-1 and GLAST expression and suppresses pain symptoms. The roles of GLT-1 and GLAST are further supported by the use of amitriptyline, a first-line drug for the NP treatment, which is shown to reverse the GLT-1 and GLAST downregulation.

Blocking JNK Signaling in Astrocytes:

The studies related to translocator protein (TSPO) linked the activation of JNK signaling with chronic pain. Mouse model of spinal nerve ligation showed that Ro5-4864, TSPO agonist, reported reduced NP and that this was attributed to inhibition of astrocyte and p-JNK1 activation. Along with this, p-ERK was also reduced, suggesting the involvement of both JNK and ERK signaling. Another JNK inhibitor, D-JNKI-1, ameliorated NP in SNL model of induced allodynia. Later, MCP-1 was identified as main downstream molecule in JNK induced pain sensitization. The association of JNK/MCP pathway was evident with the usage of drugs such as Tanshinone IIA (TIAS) that targets this signaling and showed protection against NP in SNL animal models. Animals treated with TIAS had elevated paw withdrawal threshold and reduction in astrocytic activation. Pathway analysis reported reduced JNK phosphorylation and MCP1 release in treated mice. Fluorocitrate, an astrocyte inhibitor, provided protection in development of alldynia in CPIP-injured mice. This effect was suggested to be achieved through increased spinal levels of p-JNK. SP600125 (JNK inhibitor) prevents the development of alldynia in the same mice model, and double immuno- staining showed colocalization of pJNK1/2 with GFAP, suggesting astrocytic involvement. Further studies revealed the involvement of matrix metalloproteinase-2 (MMP2) as they were upregulated. Intrathecal APR 100 (MMP-2 inhibitor) showed delayed development of alldynia with decreased levels of GFAP and pJNK1/2. This suggests the crosstalk between MMP2/JNK1/2 and MCP in astrocyte activation and pathogenesis of pain hypersensitivity. Effectiveness of SP600125 in prevention of SNLI and ddC-induced nociceptive behavior was also shown in another study where amitriptyline alone could not attenuate pain; however, when SP600125 was co-administered with amitriptyline, an antinociceptive effect was reported. It was found that p-JNK was upregulated in SNL and ddC-exposed mice and that amitriptyline treatment further increased its expression. Additionally, it promoted astrocyte activation reported by elevated glial fibrillary acidic protein (GFAP) levels. Both JNK and glial activation was attenuated by co-administration of JNK inhibitor. Thus, it can be suggested that inhibiting astrocyte JNK activation exacerbates the amitriptyline analgesic response. Modulating spinal astrocytes by targeting the JNK/MCP1 pathway can be an efficient approach against NP.

Other Astrocytes Targets for NP

Besides JNK and glutamate inhibitors, various other compounds have been tested for regulating astrogliosis in NP. One such compound is a well-known antioxidant, lycopene. Analgesic effects of lycopene were exhibited through prevention of Cx-43 protein downregulation.
Lycopene treatment increased the expression of Cx-43 protein in spinal astrocyte cultures in a TNF-dependent manner, which was found to be reduced in the NP model. Similarly, when mice with a partial sciatic nerve ligation were treated with repeated doses of lycopene, it resulted in inhibition of down regulation of Cx-43 expression in the spinal cord dorsal horn (SCDH) along with reduction in mechanical hypersensitivity.\textsuperscript{90} Pioglitazone, a PPAR\textsubscript{γ} agonist, was shown to impart analgesic effects by reducing astrocyte activation, while administration of PPAR\textsubscript{γ} antagonist GW9662 abolished these effects, suggesting involvement of PPAR\textsubscript{γ} mechanisms.\textsuperscript{91} Similarly, the analgesic activity of docosahexaenoic acid (DHA, 22:6 n-3) was confirmed in a rat model of a chronic constriction injury (CCI) where treatment with DHA showed reduced GFAP-positive astrocyte in the SCDH and ameliorated NP.\textsuperscript{92}

**Future Directions**

Although contemporary methods do not yield many results in the treatment of SCINP, glial cell-based therapies in SCI bring hope for the alleviation of symptoms and the development of a cure for NP. Because of the expansive research conducted for SCINP, there are many pathways that are available for targeting by current FDA-approved drugs and by other drugs that may still be in development. In a review,\textsuperscript{93} it has been discussed that MMPs and TIMPs should be the primary focus of clinical studies because of their extensive studies and high implication of their function in NP. In addition to MMP-2/9, JNK-1/2, astrocytes, and microglia have been found to have a critical role in NP. Many studies have shown the specific roles these tissue types play in NP, and thus it is paramount to create a treatment of NP through targeting astrocytes and microglia. Studies have shown the effects of targeting each cell type independently, but there were no studies that demonstrated the treatment of both types of cells simultaneously. This raises the possibility of a dual treatment resulting in an additive effect, thus increasing the effectiveness and efficiency of the elimination of NP. Further studies should assess the effectiveness of a dual approach of treatment of astrocytes and microglia. Coupled with that, there are efficient methods to produce specific cell types such as astrocytes and microglia from stem cells to be utilized in both study and treatment. Thus, it may be time for this method to be utilized in a clinical setting as relevant human in-vitro studies and animal model have demonstrated exceptional promise. Furthermore, because of the lack of clinical relevance of translational animal models, it is advised that labs should consider the exploration of other models, such as the WMS\textsuperscript{Tm} model–relevant as a model for human spinal cord pathlogy and practical use as a platform for developing therapeutic delivery technologies.\textsuperscript{94}

**Abbreviations**

CX43, connexin; TNF, Tumor Necrosis Factor; GLUT1, Glutamate receptor 1.
NAC, N-Acetyl-Cysteine;
DRG, Dorsal Root Ganglia;
FDA, Food and Drug Administrations;
CXCL, C-X-C Motif Chemokine 13;
CXCR, C-X-C Chemokine Receptor;
NMDAR1, N-Methyl-D-Aspartate Receptors 1;
CPIP, Chronic Post-Ischemia Pain;
GLAST, Glutamate–Aspartate Transporter;
CNS, Central Nervous System;
ATP, Adenosine Triphosphate
NMDA, N-methyl D-aspartate;
NR, Hetero-Oligomeric Proteins Receptor Subunits;
CCL, Chemokine (C-C Motif) Ligand;
MAPK, Mitogen-Activated Protein Kinases;
ERK, Extracellular-Signal-Regulated Kinase;
ROCK, Rho-Associated Protein Kinase

**Acknowledgments**

We acknowledge Dr Robert J Dempsey, Chairman, Neurological Surgery, for his constant encouragement during the study.
Authors’ Contribution

All the authors contributed to concepts, definition of intellectual content, literature search, manuscript editing, and review.

Statement of Ethics

The paper reflects the authors’ analysis in a truthful and complete manner. The paper properly credits the meaningful contributions of co-authors and co-researchers. This material is the authors’ own original work. The paper has not been previously published. All sources used are properly credited.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Parul Bali https://orcid.org/0000-0003-0849-938X
Akshay Anand https://orcid.org/0000-0001-7947-5209

References

1. Donovan J and Kirshblum S. Clinical trials in traumatic spinal cord injury. Neurotherapeutics 2018; 15: 654–668.
2. Cramer SW, Baggott C, Cain J, et al. The role of cation-dependent chloride transporters in neuropathic pain following spinal cord injury. Mol Pain 2008 September 17; 4: 36.
3. Lee HK, Ahmed MM, King KC, et al. Persistent phosphorylation of NKCC1 and WNK1 in the epicenter of the spinal cord following contusion injury. Spine J 2014 May 1; 14(5): 777–781.
4. Ahmed MM, Rajpal S, Sweeney C, et al. Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain. Spine J 2010; 10(12): 1049–1054.
5. DomBourian MG, Turner NA, Gerovac TA, et al. B1 and TRPV-1 receptor genes and their relationship to hyperalgesia following spinal cord injury. Spine (Phila Pa 1976) 2006 November 15; 31(24): 2778–2782.
6. Rajpal S, Gerovac TA, Turner NA, et al. Antihyperalgesic effects of vanilloid-1 and bradykinin-1 receptor antagonists following spinal cord injury in rats. J Neurosurg Spine 2007; 6(5): 420–424.
7. Park SW, Yi JH, Miranpuri G, et al. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007; 320(3): 1002–1012.
8. Miranpuri GS, Schomberg DT, Alrfaei B, et al. Role of matrix metalloproteinase 2 in spinal cord injury-induced neuropathic pain. Ann Neurosci 2016; 23: 25–32.
9. Miranpuri GS, Meethal SV, Sampene E, et al. Folic acid modulates MMP2 expression, alleviates neuropathic pain and improves functional recovery in spinal cord injured rats. Ann Neurosci 2017; 24: 74–81.
10. Chen G, Park CK, Xie RG, et al. Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-β secretion. J Clin Investig 2015; 125(8): 3226–3240.
11. Rock RB and Peterson PK. Microglia as a pharmacological target in infectious and inflammatory diseases of the brain. J Neuroimmune Pharmacol 2006; 1: 117–126.
12. Ginhoux F, Lim S, Hoeffel G, et al. Origin and differentiation of microglia. Front Cell Neurosci 2013 April 17; 7: 45.
13. Muffat J, Li Y, Yuan B, et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med 2016 November; 22(11): 1358–1367.
14. Chen G, Park CK, Xie RG, et al. Connexin-43 induces chemokine release from spinal cord astrocytes to maintain late-phase neuropathic pain in mice. Brain 2014 August; 137(Pt 8): 2193–2209.
15. Kawasaki Y, Xu ZZ, Wang Park JY, et al. Distinct roles of matrix metalloproteases in the early- and late phase development of neuropathic pain. Nat Med 2008 March; 14(3): 331–336.
16. Li J, Xu L, Deng X, et al. N-acetyl-cysteine attenuates neuropathic pain by suppressing matrix metalloproteinases. Pain 2016 August; 157(8): 1711–1723.
17. Welser-Alves JV, Crocker SJ, and Milner R. A dual role for microglia in promoting tissue inhibitor of metalloproteinase (TIMP) expression in glial cells in response to neuroinflammatory stimuli. J Neuroinflammation 2011; 8: 61.
18. Hains BC, Chastain KM, Everhart AW, et al. Transplants of adrenergic medullary chromaffin cells reduce forelimb and hindlimb allodynia in a rodent model of chronic central pain after spinal cord hemisection injury. Ann Neurosci 2016; 22(11): 1358–1367.
19. Hains BC, Johnson KM, Eaton MJ, et al. Engraftment of conditionally immortalized serotonergic neurons amends hyperexcitability of dorsal horn neurons after spinal hemisection-induced central sensitization. Program No. 768.11. 2001 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2001. Online.
20. Hains BC, Everhart AW, Fullwood SD, et al. Changes in serotonin, serotonin transporter expression and serotonin denervation supersensitivity: Involvement in chronic central pain after spinal hemisection in the rat. Exp Neurol 2002; 164: 426–437.
21. Hains BC, Johnson KM, Eaton MJ, et al. Serotonergic neural precursor cell grafts attenuate bilateral hyperexcitability of dorsal horn neurons after spinal hemisection-induced central sensitization. Program No. 768.11. 2001 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2001. Online.
24. Dworkin RH, O’connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc 2010; 85: S3–S14.
25. Watkins LR, Milligan ED, and Maier SF. Spinal cord glia: New players in pain. Pain 2001; 93: 201–205.
26. Donnelly DJ and Popovich PG. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol 2008; 209: 378–388.
27. McMahon SB and Malcangio M. Current challenges in glia-pain biology. Neuron 2009; 64(1): 46–54.
28. Coyle DE. Partial peripheral nerve injury leads to activation of astroglia and microglia which parallels the development of allodynic behavior. Glia 1998; 23: 75–83.
29. Jin SX, Zhuang ZY, Woolf CJ, et al. P38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 2003 May 15; 23(10): 4017–4022.
30. Ledeboer A, Sloane EM, Milligan ED, et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitates. Pain 2005; 115: 71–83.
31. Milligan ED, Twinning C, Chacur M, et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 2003; 23: 1026–1040.
32. Popovich PG, Wei P, and Stokes BT. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol 1997; 377: 443–464.
33. Sroga JM, Jones TB, Kigerl KA, et al. Rats and mice exhibit distinct inflammatory reactions after spinal cord injury. J Comp Neurol 2003; 462: 223–240.
34. Nesic O, Lee J, Johnson KM, et al. Transcriptional profiling of spinal cord injury-induced central neuropathic pain. J Neurochem 2005; 95: 998–1014
35. Zai LJ and Wrathall JR. Cell proliferation and replacement following contusive spinal cord injury. Glia 2005; 50: 247–257.
36. Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, et al. Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 2004; 45: 89–95.
37. Trang T, Beggs S, and Salter MW. ATP receptors gate microglia signaling in neuropathic pain. Exp Neurol 2012 April 1; 234(2): 354–361.
38. Ulmann L, Hatcher JP, Hughes JP, et al. Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain. J Neurosci 2008 October 29; 28(44): 11263–11268.
39. Biber K, Tsuda M, Tozaki-Saitoh H, et al. Neuronal CCL21 up-regulates microglia P2X4 expression and initiates neuropathic pain development. EMBO J 2011 May 4; 30(9): 1864–1873.
40. Tatsumi E, Yamanaka H, Kobayashi K, et al. RhoA/ROCK pathway mediates p38 MAPK activation and morphological changes downstream of P2Y12/13 receptors in spinal microglia in neuropathic pain. Glia 2015 February; 63(2): 216–228.
41. Echeverry S, Shi XQ, Yang M, et al. Spinal microglia are required for long-term maintenance of neuropathic pain. Pain 2017 September 1; 158(9): 1792–1801.
42. Liu Y, Ni Y, Zhang W, et al. N-acetyl-cysteine attenuates remifentanil-induced postoperative hyperalgesia via inhibiting matrix metalloproteinase-9 in dorsal root ganglia. Oncotarget 2017 March 7; 8(10): 16988.
43. Carlton SM, Du J, Tan HY, et al: Peripheral and central sensitization in remote spinal cord regions contribute to central neuropathic pain after spinal cord injury. Pain 2009; 147: 265–276.
44. Lee-Kubli CA, Ingvés M, Henry KW, et al. Analysis of the behavioral, cellular and molecular characteristics of pain in severe rodent spinal cord injury. Exp Neurol 2016 April 1; 278: 91–104.
45. Wang A and Xu C. The role of connexin43 in neuropathic pain induced by spinal cord injury. Acta Biochim Biophys Sin 2019; 51(6): 555–561.
46. Matyas JJ, O’Driscoll CM, Yu L, et al. Truncated TrkB. T1-Mediated Dysfunction contributes to impaired motor function and neuropathic pain after spinal cord injury. J Neurosci 2017 April 5; 37(14): 3956–3971.
47. Wu J, Renn CL, Faden AI, et al. TrkB. T1 contributes to neuropathic pain after spinal cord injury through regulation of cell cycle pathways. J Neurosci 2013 July 24; 33(30): 12447–12463.
48. Jiang BC, Cao DL, Zhang X, et al. CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5. J Clin Invest 2016 February 1; 126(2): 745–761.
49. Tang J, Zhu C, Li ZH, et al. Inhibition of the spinal astrocytic JNK/MCP-1 pathway activation correlates with the analgesic effects of tanshinone IIA sulfonate in neuropathic pain. J Neuroinflammation 2015 December; 12(1): 1–2.
50. Jiang L, Pan CL, Wang CY, et al. Selective suppression of the JNK-MMP2/9 signal pathway by tetramethylpyrazine attenuates neuropathic pain in rats. J Neuroinflammation 2017 December; 14(1): 1–2.
51. Tian Guogang, Xin Luo, Chaoliang Tang, et al. Astrocyte contributes to pain development via MMP2-JNK1/2 signaling in a mouse model of complex regional pain syndrome. Life Sci 2017; 170: 64–71.
52. Meller ST, Dykstra C, Grazymbcki D, et al. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology 1994 November; 33(11): 1471–1478.
53. Sweitzer SM, Schubert P, and DeLeo JA. Propentofylline, a glial modulating agent, exhibits antiinflammatory properties in a rat model of neuropathic pain. J Pharmacol Exp Ther 2001; 297: 1210–1217.
54. Ji RR and Suter MR. p38 MAPK, microglial signaling, and neuropathic pain. Mole Pain 2007 November 1; 3: 107: 312–321.
55. Tawfik VL, Nutile-McMenemy N, LaCroix-Fralish ML, et al. Efficacy of propentofylline, a glial modulating agent, on exist-
ing and neuropathic pain. J Neurosci 2008 March 12; 28(11): 2892–2902.

59. Trang T, Beggs S, Wan X, et al. P2X4-receptor-mediated synthesis and release of brain-derived neurotrophic factor in microglia is dependent on calcium and p38-mitogen-activated protein kinase activation. J Neurosci 2009; 29: 3518–3528.

60. Biggs JE, Van Lu B, Stebbing MJ, et al. Is BDNF sufficient for information transfer between microglia and dorsal horn neurons during the onset of central sensitization? Mole Pain 2010 July 23; 6: 1744–8069.

61. Lever I, Cunningham J, Grist J, et al. Release of BDNF and GABA in the dorsal horn of neuropathic rats. Eur J Neurosci 2003; 18: 1169–1174.

62. Lu VB, Ballanyi K, Colmers WF, et al. Neuron type-specific effects of brain-derived neurotrophic factor in rat superficial dorsal horn and their relevance to ‘central sensitization’. J Physiol 2007; 584: 543–563.

63. Chessell IP, Hatcher JP, Bountra C, et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005; 114: 386–396.

64. Broom DC, Matson DJ, Bradshaw E, et al. Characterization of N-(adamantan-1-ylmethyl)-5-(3R-aminopyrrolidin-1-yl) methyl)-2-chloro-benzamide, a P2X7 antagonist in animal models of pain and inflammation. The Journal of Pharmacology and experimental therapeutics 2008 December 1; 327(3): 620–633.

65. Honore P, Donnelly-Roberts D, Namovic M, et al. The anti-hyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1β knockout mice. Behav Brain Res 2009 December 1; 204(1): 77–81.

66. Clark AK, Wodarski R, Guida F, et al. Cathepsin S release from microglia is dependent on calcium and p38-mitogen-activated protein kinase activation. J Neurosci 2009; 29: 4096–4108.

67. Suzuki H, Gershenson DM, and Aizawa K. Matrix metalloproteinase-9 activity and expression is reduced by melatonin during prevention of ethanol-induced gastric ulcer in mice. J Pineal Res 2007 August; 43(1): 56–64.

68. Dzowneck J, Ryksli M, and Kaczmarek L. Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett 2004; 567: 129–135.

69. Hu Y, Li W, Lu L, et al. An anti-nociceptive role for ceftriaxone in chronic neuropathic pain in rats. Pain 2010 February 1; 148(2): 284–301.

70. Tawfik VL, Regan MR, Haenggeli C, et al. Propentofylline-induced astrocyte modulation leads to alterations in glial glutamate promoter activation following spinal nerve injury. Neurosci Research 2008 April 9; 152(4): 1086–1092.

71. Mao L, Wang H, Qiao L, et al. Disruption of Nrf2 enhances the upregulation of nuclear factor-kappaB activity, tumor necrosis factor-, and matrix metalloproteinase-9 after spinal cord injury in mice. Mole Neurobiol 2010; 2010: 238321.
91. Griggs RB, Donahue RR, Morgenweck J, et al. Pioglitazone rapidly reduces neuropathic pain through astrocyte and non-genomic PPARγ mechanisms. Pain 2015 March; 156 (3): 469–482.

92. Manzhulo IV, Ogurtsova OS, Kipryushina YO, et al. Neuron-astrocyte interactions in spinal cord dorsal horn in neuropathic pain development and docosahexaenoic acid therapy. J Neuroimmunol 2016 September 15; 298: 90–97.

93. Ahmed MM, King KC, Pearce SM, et al. Novel targets for spinal cord injury related neuropathic pain. Ann Neurosci 2011 October; 18(4):162–167.

94. Miranpuri GS, Schomberg DT, Stan P, et al. Comparative Morphometry of the Wisconsin Miniature SwineTM Thoracic Spine for Modeling Human Spine in Translational Spinal Cord Injury Research. Ann Neurosci 2018; 25: 210–218.